UroGen Pharma Ltd

(NASDAQ:URGN)

Latest On UroGen Pharma Ltd (URGN):

Date/Time Type Description Signal Details
2023-05-12 01:46 ESTNewsUrogen Pharma Ltd (URGN) Q1 2023 Earnings Call TranscriptN/A
2023-05-11 11:35 ESTNewsUroGen Pharma GAAP EPS of -$1.30 beats by $0.01, revenue of $17.19M beats by $0.1MN/A
2023-05-01 14:45 ESTNewsUroGen Pharma jumps amid takeover speculationN/A
2023-03-17 00:28 ESTNewsUroGen Pharma Ltd. (URGN) Q4 2022 Earnings Call TranscriptN/A
2023-03-16 08:54 ESTNewsUroGen Pharma GAAP EPS of -$1.22 misses by $0.14, revenue of $18.09M misses by $0.42MN/A
2023-02-08 13:43 ESTNewsUroGen: Struggling With Revenue And With Cash RunwayN/A
2023-02-08 13:42 ESTNewsUroGen Pharma falls after Jefferies lower rating to holdN/A
2022-11-21 16:23 ESTNewsUroGen Pharma: Jelmyto Sales Growing Steadily, Concerns RemainN/A
2022-11-11 00:31 ESTNewsUroGen Pharma GAAP EPS of -$1.13 beats by $0.05, revenue of $16.1M misses by $4.05MN/A
2022-11-11 00:31 ESTNewsUroGen Pharma Ltd. (URGN) Q3 2022 Earnings Call TranscriptN/A
2022-09-29 01:36 ESTNewsUroGen gets FDA nod for extending duration of Jelmyto admixtureN/A
2022-08-11 16:57 ESTNewsUroGen Pharma GAAP EPS of -$1.18 beats by $0.12, revenue of $16.6M misses by $0.68M, reaffirms FY revenue guidanceN/A
2022-08-11 16:57 ESTNewsUrogen Pharma Ltd (URGN) CEO Elizabeth Barrett on Q2 2022 Results - Earnings Call TranscriptN/A
2022-05-11 11:36 ESTNewsUroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-10 15:51 ESTNewsUroGen Pharma GAAP EPS of -$1.25 beats by $0.09, revenue of $13.56M misses by $1.62MN/A
2022-04-27 12:58 ESTNewsUroGen wins Buy rating at Berenberg on potential in bladder cancerN/A
2022-03-29 13:44 ESTNewsUroGen Pharma gets FDA nod to begin phase 1 trial of UGN-301 for bladder cancerN/A
2022-03-22 05:43 ESTNewsUroGen Pharma GAAP EPS of -$1.27 misses by $0.07, revenue of $16.17M misses by $0.32MN/A
2022-03-22 05:42 ESTNewsUroGen Pharma Ltd.'s (URGN) CEO Liz Barrett on Q4 2021 Results - Earnings Call TranscriptN/A
2022-02-03 18:51 ESTNewsUroGen begins phase 3 trial of UGN-102 to treat bladder cancerN/A
2021-12-03 22:14 ESTNewsUroGen pharma reports inducement grant to 13 new employeesN/A
2021-11-19 21:27 ESTNewsUrogen Pharma (URGN) Investor Presentation - SlideshowN/A
2021-11-15 14:17 ESTNewsUroGen Pharma EPS misses by $0.06, misses on revenueN/A
2021-11-15 14:17 ESTNewsUroGen Pharma slips on Q3 earnings miss and disappointing guidanceN/A
2021-11-15 14:16 ESTNewsUroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q3 2021 Results - Earnings Call TranscriptN/A
2021-10-05 17:37 ESTNewsUroGen bladder cancer candidate shows meaningful, durable response in mid-stage trialN/A
2021-08-07 08:17 ESTNewsUroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-04 17:03 ESTNewsUroGen Pharma EPS in-line, beats on revenueN/A
2021-07-29 06:21 ESTNewsUroGen Pharma inks license and supply agreement with NeopharmN/A
2021-07-22 05:19 ESTNewsUroGen Pharma sees Q2 net revenue of $13M, above consensusN/A
2021-07-22 05:12 ESTNewsUroGen Pharma (URGN) Presents At HealthVirtual Conference - SlideshowN/A
2021-03-19 04:02 ESTNewsUroGen Pharma EPS misses by $0.01, beats on revenueN/A
2021-03-19 04:02 ESTNewsUroGen Pharma to receive $75M non-dilutive funding from RTW InvestmentsN/A
2021-03-19 04:00 ESTNewsUroGen Pharma Ltd.'s (URGN) CEO Liz Barrett on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-18 07:00 ESTNewsUrogen Pharma (URGN) Presents At Oppenheimer 31st Annual Healthcare Conference - SlideshowN/A
2021-03-02 02:15 ESTNewsJelmyto And UGN-102 Will Likely Drive Strong Returns For UroGen ShareholdersN/A
2021-01-21 00:41 ESTNewsUrogen Pharma (URGN) Presents At 39th Annual J.P. Morgan Healthcare Conference - SlideshowN/A
2021-01-13 19:56 ESTNewsUroGen Pharma teams up with MD Anderson to advance treatment for bladder cancerN/A
2021-01-11 09:16 ESTNewsUroGen Is Worth $50/Share, Should It Trade At Revenue Multiples Consistent With Its PeersN/A
2021-01-10 19:55 ESTNewsURGN Is Worth $50/Share Should It Trade At Revenue Multiples Consistent With Its PeersN/A
2021-01-05 12:58 ESTAnalyst RatingThe Analyst Target Price has decreased from $43 to $41.Neutral
2020-11-26 21:54 ESTFinancialsCompany financials have been released.Neutral
2020-11-11 13:19 ESTFinancialsCompany financials have been released.Neutral
2020-11-11 05:19 ESTAnalyst RatingThe Analyst Target Price has decreased from $44.14 to $43.Neutral
2020-11-10 13:24 ESTEarnings EstimateAn EPS average of -$1.33 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-09 21:42 ESTNewsUroGen Pharma EPS beats by $0.15, beats on revenueN/A
2020-11-09 21:40 ESTNewsUroGen Pharma's (URGN) CEO Liz Barrett on Q3 2020 Results - Earnings Call TranscriptN/A
2020-11-08 01:12 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 17:27 ESTFinancialsCompany financials have been released.Neutral
2020-10-30 10:13 ESTInsider TradeMark Schoenberg has directly disposed of 101 shares and currently holds 19,343 shares.Sell

About UroGen Pharma Ltd (URGN):

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases. The company's lead product candidates are UGN-101 and UGN-102, which are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-201, a proprietary immunotherapy product candidate for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. It also has a strategic research agreement with the Johns Hopkins University to study the checkpoint inhibitors combined with RTGel in glioblastoma multiforme to treat brain cancer. UroGen Pharma Ltd. was founded in 2004 and is based in Princeton, New Jersey.

URGN Quotes by TradingView

See Advanced Chart

General

  • Name UroGen Pharma Ltd
  • Symbol URGN
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 187
  • Fiscal Year EndDecember
  • IPO Date2017-05-04
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.urogen.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 110.91
  • Price/Book (Most Recent Quarter) 3.63
  • Enterprise Value Revenue 83.61
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$1.44
  • Operating Margin -3463%
  • Return on Assets -45%
  • Return on Equity -83%
  • Revenue 3.83 million
  • Earnings Per Share -$4.89
  • Revenue Per Share $0.18
  • Gross Profit 18000
  • Quarterly Earnings Growth 1966.7%
View More

Highlights

  • Market Capitalization 423.52 million
  • EBITDA -81143000
  • Analyst Target Price $41
  • Book Value Per Share $5.46
View More

Share Statistics

  • Shares Outstanding 22.09 million
  • Shares Float 18.76 million
  • % Held by Insiders 1274%
  • % Held by Institutions 75.18%
  • Shares Short 2.76 million
  • Shares Short Prior Month 2.72 million
  • Short Ratio 15.65
  • Short % of Float 16%
  • Short % of Shares Outstanding 13%
View More

Technicals

  • Beta 1.23
  • 52 Week High $30.89
  • 52 Week Low $13.12
  • 50 Day Moving Average 22.09
  • 200 Day Moving Average 21.19
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

UroGen Pharma Ltd (URGN) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

UroGen Pharma Ltd (URGN) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-09$N/A-$1.31-$1.4711.1%
2020-06-302020-08-10$N/A-$1.44-$1.525.16%
2020-03-312020-05-07$N/A-$1.79-$1.58-13.16%
2019-12-312020-03-02$N/A-$1.86-$1.70-9.57%
2019-09-302019-11-12$N/A-$1.06-$1.2817.42%
2019-06-302019-08-09$18000-$1.08-$1.209.93%
2019-03-312019-05-09$N/A-$1.11-$1.2712.25%
2018-12-312019-02-28$845000-$1.46-$1.28-14.51%
2018-09-302018-11-12$283000-$1.28-$1.11-15.32%
2018-06-302018-08-14$364000-$1.14-$0.93-22.58%
2018-03-312018-05-15$481000-$0.88-$0.63-39.68%
2017-12-312018-03-15$327000-$0.74-$0.64-16.22%
2017-09-302017-11-14$7.81 million-$0.02$0.11-118.18%
2017-06-302017-08-14$-38000-$0.68-$1.7761.58%

UroGen Pharma Ltd (URGN) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Research Development N/A N/A N/A 20.09 million 9.48 million
Income Before Tax N/A N/A N/A -38.97 million -22.25 million
Selling General Administrative N/A N/A N/A 19.75 million 13.97 million
Gross Profit N/A N/A N/A N/A N/A
Ebit N/A N/A N/A -39.84 million -23.45 million
Operating Income N/A N/A N/A -39.84 million -23.45 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A 866000 1.2 million
Net Income From Continuing Operations N/A N/A N/A -38.97 million -22.25 million
Net Income Applicable to Common Shares -28.82 million -31.35 million -37.79 million -38.97 million -22.25 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A 9.66 million -12.61 million
Change to Liabilities -460000 452000 -2.5 million 3.12 million 809000
Total Cash Flow from Investing Activities 13.23 million 17.51 million 13.03 million 9.3 million -12.66 million
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A N/A 245000 1.13 million
Change to Operating Activities -179000 1.15 million -3.15 million 1.76 million 1.94 million
Change in Cash N/A N/A N/A -16.46 million -24.06 million
Total Cash from Operating Activities -25.08 million -23.93 million -35.64 million -26 million -12.53 million
Depreciation N/A N/A N/A 1.14 million 65000
Other Cash Flow from Investing Activities N/A N/A N/A -168000 N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities -55000 203000 -203000 -76000 N/A
Change to Net Income 6.51 million 6.87 million 7.35 million 6.96 million 6.91 million
Capital Expenditures N/A N/A N/A 192000 49000
Balance Sheet:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Total Liabailities N/A N/A N/A 22.09 million 15.84 million
Total Stockholder Equity N/A N/A N/A 180.3 million 210.92 million
Other Current Liabilities 1.34 million N/A N/A N/A 1.13 million
Total Assets N/A N/A N/A 202.39 million 226.75 million
Common Stock 60000 60000 58000 57000 57000
Other Current Assets 1.22 million N/A N/A 523000 523000
Retained Earnings -325.98 million -297.16 million -265.81 million -228.02 million -189.04 million
Other Liabilities N/A N/A N/A N/A N/A
Other Assets 278000 223000 502000 487000 2.48 million
Cash N/A N/A N/A 49.69 million 66.15 million
Total Current Liabilities 17.62 million N/A N/A 19.48 million 14.09 million
Other Stockholder Equity 492000 760000 311000 276000 303000
Property, Plant & Equipment 4.38 million 4.41 million 4.42 million 4.71 million 893000
Total Current Assets 129.34 million N/A N/A 148.63 million 159.88 million
Long Term Investments N/A N/A N/A 48.56 million 63.51 million
Net Tangible Assets 120.53 million 142.66 million 150.45 million 180.3 million 210.92 million
Short Term Investments N/A N/A N/A 97.39 million 92.05 million
Long Term Debt N/A N/A N/A N/A N/A
Inventory 1.35 million N/A N/A N/A N/A
Accounts Payable 8.49 million N/A N/A 4.69 million 7.88 million

UroGen Pharma Ltd (URGN) Chart:

UroGen Pharma Ltd (URGN) News:

Below you will find a list of latest news for UroGen Pharma Ltd (URGN) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

UroGen Pharma Ltd (URGN) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-172.50CALL0 0821.11TRUE00
2024-05-1750CALL0 0546.29TRUE00
2024-05-177.50CALL0 0404.72TRUE00
2024-05-17104.57CALL0 1252.84TRUE00
2024-05-1712.52.5CALL13 38139.88TRUE0.20.09
2024-05-17150.95CALL3 31574.24FALSE0.230.32
2024-05-1717.50.25CALL0 225120.73FALSE00
2024-05-17200.15CALL0 42208.43FALSE00
2024-05-1722.51.25CALL0 200FALSE00
2024-05-17250.15CALL0 1970FALSE00
2024-05-17300.05CALL0 180FALSE00
2024-05-17350CALL0 00FALSE00
2024-05-172.50PUT0 00FALSE00
2024-05-1750PUT0 00FALSE00
2024-05-177.50.19PUT0 120FALSE00
2024-05-17100.59PUT0 100FALSE00
2024-05-1712.50.35PUT1 432100.51FALSE0.350
2024-05-17152.05PUT0 12095.68TRUE00
2024-05-1717.53.6PUT0 38138.81TRUE00
2024-05-17207.1PUT0 20185.1TRUE00
2024-05-1722.50PUT0 0200.58TRUE00
2024-05-17250PUT0 0212.89TRUE00
2024-05-17300PUT0 0279.48TRUE00
2024-05-173519.75PUT0 0236.5TRUE00
2024-06-212.50CALL0 0482.31TRUE00
2024-06-2150CALL0 0418.44TRUE00
2024-06-217.50CALL0 0242.92TRUE00
2024-06-21104.97CALL0 4173.91TRUE00
2024-06-2112.54.2CALL3 23166.62TRUE0.980.3
2024-06-21151.58CALL0 2293.12FALSE00
2024-06-2117.51CALL0 793.1FALSE00
2024-06-21200.6CALL1 199.88FALSE0.60
2024-06-2122.50.4CALL1 1105FALSE0.40
2024-06-21250CALL0 00FALSE00
2024-06-21300CALL0 00FALSE00
2024-06-212.50PUT0 00FALSE00
2024-06-2150PUT0 00FALSE00
2024-06-217.50PUT0 00FALSE00
2024-06-21100.36PUT0 20153.35FALSE00
2024-06-2112.51.5PUT0 200121.18FALSE00
2024-06-21150PUT0 0101.5TRUE00
2024-06-2117.50PUT0 0144.77TRUE00
2024-06-21200PUT0 0124.1TRUE00
2024-06-2122.50PUT0 0142.66TRUE00
2024-06-21250PUT0 0154.43TRUE00
2024-06-21300PUT0 0169.31TRUE00
2024-07-192.50CALL0 0335.98TRUE00
2024-07-1950CALL0 0246.45TRUE00
2024-07-197.50CALL0 0191.54TRUE00
2024-07-19100CALL0 0151.03TRUE00
2024-07-1912.50CALL0 096.81TRUE00
2024-07-19150CALL0 097.2FALSE00
2024-07-1917.52.17CALL0 690112.98FALSE00
2024-07-19200CALL0 0129.29FALSE00
2024-07-1922.50CALL0 0131.47FALSE00
2024-07-19250CALL0 0138.17FALSE00
2024-07-192.50PUT0 00FALSE00
2024-07-1950PUT0 00FALSE00
2024-07-197.50PUT0 00FALSE00
2024-07-19100PUT0 0130.03FALSE00
2024-07-1912.50PUT0 090.53FALSE00
2024-07-19152.71PUT0 68095.42TRUE00
2024-07-1917.50PUT0 085.19TRUE00
2024-07-19200PUT0 0133.75TRUE00
2024-07-1922.50PUT0 0129.28TRUE00
2024-07-19250PUT0 0130.56TRUE00
2024-08-162.50CALL0 0285.88TRUE00
2024-08-16513.07CALL0 1239.26TRUE00
2024-08-167.50CALL0 0165.82TRUE00
2024-08-16105.45CALL0 21118.16TRUE00
2024-08-1612.50CALL0 0101.79TRUE00
2024-08-16152.2CALL0 36494.82FALSE00
2024-08-1617.51CALL0 4386.01FALSE00
2024-08-16201.3CALL0 2492.67FALSE00
2024-08-1622.52.85CALL0 4109.17FALSE00
2024-08-16251.5CALL0 2794.91FALSE00
2024-08-16300.4CALL0 14791.65FALSE00
2024-08-16351.15CALL0 150FALSE00
2024-08-162.50PUT0 00FALSE00
2024-08-1650PUT0 00FALSE00
2024-08-167.50PUT0 0119.85FALSE00
2024-08-16101.05PUT0 20100.34FALSE00
2024-08-1612.52.5PUT0 5114.36FALSE00
2024-08-16153.25PUT0 565.2TRUE00
2024-08-1617.54.78PUT0 391.1TRUE00
2024-08-16207.4PUT0 596.9TRUE00
2024-08-1622.57.4PUT0 35101.06TRUE00
2024-08-16259.32PUT0 1121.72TRUE00
2024-08-16300PUT0 097.64TRUE00
2024-08-163519.25PUT0 0134.98TRUE00
2024-11-152.50CALL0 0205.48TRUE00
2024-11-1550CALL0 0179.19TRUE00
2024-11-157.50CALL0 0135.14TRUE00
2024-11-15100CALL0 0105.05TRUE00
2024-11-1512.50CALL0 080.46TRUE00
2024-11-15153.2CALL0 1079.11FALSE00
2024-11-1517.52.65CALL0 2584.18FALSE00
2024-11-15200CALL0 083.3FALSE00
2024-11-1522.50CALL0 095.78FALSE00
2024-11-15250CALL0 085.52FALSE00
2024-11-15300CALL0 086.04FALSE00
2024-11-15351.1CALL0 191.39FALSE00
2024-11-152.50PUT0 00FALSE00
2024-11-1550PUT0 00FALSE00
2024-11-157.50PUT0 0120.8FALSE00
2024-11-15100PUT0 0103.95FALSE00
2024-11-1512.51.95PUT0 094.7FALSE00
2024-11-15150PUT0 078.59TRUE00
2024-11-1517.50PUT0 068.28TRUE00
2024-11-15200PUT0 084.52TRUE00
2024-11-1522.50PUT0 088.97TRUE00
2024-11-15250PUT0 0109.53TRUE00
2024-11-15300PUT0 0107.21TRUE00
2024-11-153518.95PUT0 0112.63TRUE00

Latest URGN Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST5$6.56
Jun 13, 2022 7:59 PM EST16$6.56
Jun 13, 2022 7:59 PM EST42$6.58
Jun 13, 2022 7:59 PM EST100$6.57
Jun 13, 2022 7:59 PM EST100$6.57

UroGen Pharma Ltd (URGN) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120035684/0001209191-20-035684-index.htm
2018-10-24UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1668243/000000000018033311/0000000000-18-033311-index.htm
2019-05-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1668243/000000000019008192/0000000000-19-008192-index.htm
2019-05-17UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1668243/000000000019008687/0000000000-19-008687-index.htm
2019-05-30UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1668243/000000000019009150/0000000000-19-009150-index.htm
2019-12-27UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1668243/000000000019016806/0000000000-19-016806-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1668243/000031506619001377/0000315066-19-001377-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1668243/000083423720007990/0000834237-20-007990-index.htm
2019-02-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1668243/000090221919000060/0000902219-19-000060-index.htm
2020-01-27SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1668243/000090221920000110/0000902219-20-000110-index.htm
2018-08-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1668243/000095012318008882/0000950123-18-008882-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1668243/000108514619000751/0001085146-19-000751-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1668243/000108514620000852/0001085146-20-000852-index.htm
2019-01-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1668243/000114420419001440/0001144204-19-001440-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1668243/000117891319000488/0001178913-19-000488-index.htm
2019-06-03SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1668243/000117891319001642/0001178913-19-001642-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1668243/000117891320000371/0001178913-20-000371-index.htm
2020-02-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1668243/000117891320000395/0001178913-20-000395-index.htm
2018-07-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1668243/000119312518217088/0001193125-18-217088-index.htm
2018-08-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1668243/000119312518242444/0001193125-18-242444-index.htm
2018-08-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1668243/000119312518263657/0001193125-18-263657-index.htm
2018-09-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1668243/000119312518275855/0001193125-18-275855-index.htm
2018-09-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1668243/000119312518279401/0001193125-18-279401-index.htm
2018-10-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1668243/000119312518287790/0001193125-18-287790-index.htm
2018-10-12F-3Registration statement by foreign private issuershttps://www.sec.gov/Archives/edgar/data/1668243/000119312518298482/0001193125-18-298482-index.htm
2018-10-12S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1668243/000119312518298488/0001193125-18-298488-index.htm
2018-10-24CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1668243/000119312518306177/0001193125-18-306177-index.htm
2018-10-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1668243/000119312518313813/0001193125-18-313813-index.htm
2019-01-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1668243/000119312519001714/0001193125-19-001714-index.htm
2019-01-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1668243/000119312519005114/0001193125-19-005114-index.htm
2019-01-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1668243/000119312519014088/0001193125-19-014088-index.htm
2019-01-22424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1668243/000119312519014093/0001193125-19-014093-index.htm
2019-01-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1668243/000119312519016388/0001193125-19-016388-index.htm
2019-01-25424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1668243/000119312519016433/0001193125-19-016433-index.htm
2019-02-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1668243/000119312519055714/0001193125-19-055714-index.htm
2019-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1668243/000119312519122589/0001193125-19-122589-index.htm
2019-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1668243/000119312519142301/0001193125-19-142301-index.htm
2019-05-14CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1668243/000119312519146553/0001193125-19-146553-index.htm
2019-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1668243/000119312519158432/0001193125-19-158432-index.htm
2019-05-29CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1668243/000119312519159661/0001193125-19-159661-index.htm
2019-06-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1668243/000119312519168284/0001193125-19-168284-index.htm
2019-06-07S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1668243/000119312519168298/0001193125-19-168298-index.htm
2019-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1668243/000119312519217507/0001193125-19-217507-index.htm
2019-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1668243/000119312519253710/0001193125-19-253710-index.htm
2019-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1668243/000119312519288338/0001193125-19-288338-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1668243/000119312519289211/0001193125-19-289211-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1668243/000119312519289316/0001193125-19-289316-index.htm
2019-11-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1668243/000119312519298551/0001193125-19-298551-index.htm
2019-12-20S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1668243/000119312519320929/0001193125-19-320929-index.htm
2019-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1668243/000119312519320975/0001193125-19-320975-index.htm
2019-12-30CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1668243/000119312519325909/0001193125-19-325909-index.htm
2020-01-02424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1668243/000119312520000672/0001193125-20-000672-index.htm
2020-03-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1668243/000119312520081537/0001193125-20-081537-index.htm
2020-04-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1668243/000119312520108412/0001193125-20-108412-index.htm
2020-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1668243/000119312520143480/0001193125-20-143480-index.htm
2020-06-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1668243/000119312520165697/0001193125-20-165697-index.htm
2020-08-10S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1668243/000119312520215023/0001193125-20-215023-index.htm
2020-08-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1668243/000119312520232097/0001193125-20-232097-index.htm
2020-09-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1668243/000119312520241611/0001193125-20-241611-index.htm
2019-01-093Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119003113/0001209191-19-003113-index.htm
2019-01-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119003174/0001209191-19-003174-index.htm
2019-01-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119003281/0001209191-19-003281-index.htm
2019-01-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119003282/0001209191-19-003282-index.htm
2019-01-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119003283/0001209191-19-003283-index.htm
2019-01-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119003284/0001209191-19-003284-index.htm
2019-01-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119003285/0001209191-19-003285-index.htm
2019-01-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119003286/0001209191-19-003286-index.htm
2019-01-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119003287/0001209191-19-003287-index.htm
2019-01-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119003288/0001209191-19-003288-index.htm
2019-01-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119003289/0001209191-19-003289-index.htm
2019-01-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119003291/0001209191-19-003291-index.htm
2019-01-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119003292/0001209191-19-003292-index.htm
2019-01-153/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119003804/0001209191-19-003804-index.htm
2019-01-153/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119003805/0001209191-19-003805-index.htm
2019-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119005801/0001209191-19-005801-index.htm
2019-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119005803/0001209191-19-005803-index.htm
2019-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119005805/0001209191-19-005805-index.htm
2019-03-073/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119017931/0001209191-19-017931-index.htm
2019-03-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119017932/0001209191-19-017932-index.htm
2019-03-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119017933/0001209191-19-017933-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119021091/0001209191-19-021091-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119021092/0001209191-19-021092-index.htm
2019-03-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119021635/0001209191-19-021635-index.htm
2019-05-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119030594/0001209191-19-030594-index.htm
2019-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119034777/0001209191-19-034777-index.htm
2019-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119034780/0001209191-19-034780-index.htm
2019-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119034785/0001209191-19-034785-index.htm
2019-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119034787/0001209191-19-034787-index.htm
2019-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119034788/0001209191-19-034788-index.htm
2019-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119034790/0001209191-19-034790-index.htm
2019-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119034793/0001209191-19-034793-index.htm
2019-06-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119035245/0001209191-19-035245-index.htm
2019-08-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119046282/0001209191-19-046282-index.htm
2019-08-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119047107/0001209191-19-047107-index.htm
2019-09-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119048672/0001209191-19-048672-index.htm
2019-11-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119056923/0001209191-19-056923-index.htm
2019-11-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119057044/0001209191-19-057044-index.htm
2019-11-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119057692/0001209191-19-057692-index.htm
2019-11-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119057753/0001209191-19-057753-index.htm
2019-11-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119057755/0001209191-19-057755-index.htm
2019-11-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119057766/0001209191-19-057766-index.htm
2019-12-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919119059250/0001209191-19-059250-index.htm
2020-01-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120002366/0001209191-20-002366-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120005200/0001209191-20-005200-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120005211/0001209191-20-005211-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120005215/0001209191-20-005215-index.htm
2020-02-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120006208/0001209191-20-006208-index.htm
2020-02-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120006210/0001209191-20-006210-index.htm
2020-02-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120006211/0001209191-20-006211-index.htm
2020-02-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120006212/0001209191-20-006212-index.htm
2020-02-133/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120009118/0001209191-20-009118-index.htm
2020-02-133/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120009122/0001209191-20-009122-index.htm
2020-02-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120009943/0001209191-20-009943-index.htm
2020-02-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120012017/0001209191-20-012017-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120016275/0001209191-20-016275-index.htm
2020-04-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120025893/0001209191-20-025893-index.htm
2020-04-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120025903/0001209191-20-025903-index.htm
2020-04-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120025904/0001209191-20-025904-index.htm
2020-05-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120029079/0001209191-20-029079-index.htm
2020-05-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120030900/0001209191-20-030900-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120034672/0001209191-20-034672-index.htm
2020-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120035676/0001209191-20-035676-index.htm
2020-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120035677/0001209191-20-035677-index.htm
2020-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120035678/0001209191-20-035678-index.htm
2020-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120035679/0001209191-20-035679-index.htm
2020-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120035680/0001209191-20-035680-index.htm
2020-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120035682/0001209191-20-035682-index.htm
2020-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120035684/0001209191-20-035684-index.htm
2020-07-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120043873/0001209191-20-043873-index.htm
2020-07-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120043874/0001209191-20-043874-index.htm
2020-09-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120048883/0001209191-20-048883-index.htm
2020-09-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120049741/0001209191-20-049741-index.htm
2020-09-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120049936/0001209191-20-049936-index.htm
2020-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120049937/0001209191-20-049937-index.htm
2020-10-054/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120053632/0001209191-20-053632-index.htm
2020-10-053Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120053637/0001209191-20-053637-index.htm
2020-10-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120053641/0001209191-20-053641-index.htm
2020-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120055037/0001209191-20-055037-index.htm
2020-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1668243/000120919120056066/0001209191-20-056066-index.htm
2019-10-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1668243/000138713119007448/0001387131-19-007448-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1668243/000138713120001809/0001387131-20-001809-index.htm
2018-11-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1668243/000156459018029081/0001564590-18-029081-index.htm
2019-02-2810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1668243/000156459019005323/0001564590-19-005323-index.htm
2019-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1668243/000156459019017568/0001564590-19-017568-index.htm
2019-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1668243/000156459019031042/0001564590-19-031042-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1668243/000156459019042553/0001564590-19-042553-index.htm
2020-03-0210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1668243/000156459020007970/0001564590-20-007970-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1668243/000156459020019410/0001564590-20-019410-index.htm
2020-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1668243/000156459020019415/0001564590-20-019415-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1668243/000156459020022352/0001564590-20-022352-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1668243/000156459020038598/0001564590-20-038598-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1668243/000156459020038611/0001564590-20-038611-index.htm
2018-10-26EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1668243/999999999518002728/9999999995-18-002728-index.htm
2020-01-02EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1668243/999999999520000010/9999999995-20-000010-index.htm

UroGen Pharma Ltd (URGN) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of UroGen Pharma Ltd (URGN). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1274%
Institutional Ownership: 7518%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-04-27Stephen MullennixChief Operating OfficerSell145.0024.353,530.7510,084.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120025893/0001209191-20-025893-index.htm
2020-04-26Stephen MullennixChief Operating OfficerBuy417.0010,229.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120025893/0001209191-20-025893-index.htm
2020-10-15PETER P. PFREUNDSCHUHChief Financial OfficerSell1,017.0021.7222,089.2410,405.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120055037/0001209191-20-055037-index.htm
2020-02-14Stephen MullennixChief Operating OfficerBuy1,759.0010,424.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120009943/0001209191-20-009943-index.htm
2020-10-15PETER P. PFREUNDSCHUHChief Financial OfficerSell407.0021.828,882.4911,422.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120055037/0001209191-20-055037-index.htm
2020-10-15PETER P. PFREUNDSCHUHChief Financial OfficerSell976.0021.8021,276.0211,829.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120055037/0001209191-20-055037-index.htm
2020-01-03Elizabeth A. BarrettChief Executive OfficerBuy105,688.00122,236.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120002366/0001209191-20-002366-index.htm
2020-10-15PETER P. PFREUNDSCHUHChief Financial OfficerBuy4,917.0012,805.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120055037/0001209191-20-055037-index.htm
2019-02-06Fred E CohenDirectorBuy15,000.0016.99254,850.0015,000.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119021091/0001209191-19-021091-index.htm
2019-11-15Elizabeth A. BarrettChief Executive OfficerBuy1,548.0026.0040,248.001,548.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119057044/0001209191-19-057044-index.htm
2020-05-12Elizabeth A. BarrettChief Executive OfficerBuy35,229.00157,465.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120029079/0001209191-20-029079-index.htm
2019-11-21Elizabeth A. BarrettChief Executive OfficerBuy7,530.0028.00210,840.0016,548.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119057766/0001209191-19-057766-index.htm
2020-04-27Mark SchoenbergChief Medical OfficerSell70.0024.351,704.5017,711.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120025904/0001209191-20-025904-index.htm
2020-04-26Mark SchoenbergChief Medical OfficerBuy208.0017,781.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120025904/0001209191-20-025904-index.htm
2020-03-04Mark SchoenbergChief Medical OfficerBuy1,042.0017,918.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120016275/0001209191-20-016275-index.htm
2020-06-04Mark SchoenbergChief Medical OfficerSell349.0027.519,601.9718,404.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120034672/0001209191-20-034672-index.htm
2020-07-27Mark SchoenbergChief Medical OfficerSell70.0023.511,645.7018,543.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120043873/0001209191-20-043873-index.htm
2020-07-26Mark SchoenbergChief Medical OfficerBuy209.0018,613.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120043873/0001209191-20-043873-index.htm
2020-06-04Mark SchoenbergChief Medical OfficerBuy1,042.0018,753.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120034672/0001209191-20-034672-index.htm
2020-09-04Mark SchoenbergChief Medical OfficerSell348.0020.207,029.6019,236.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120049741/0001209191-20-049741-index.htm
2020-10-26Mark SchoenbergChief Medical OfficerSell101.0020.952,115.5619,343.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120056066/0001209191-20-056066-index.htm
2020-10-26Mark SchoenbergChief Medical OfficerBuy208.0019,444.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120056066/0001209191-20-056066-index.htm
2020-09-04Mark SchoenbergChief Medical OfficerBuy1,041.0019,584.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120049741/0001209191-20-049741-index.htm
2019-03-27Arie BelldegrunDirectorBuy128,000.004.02514,560.00212,211.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119021635/0001209191-19-021635-index.htm
2019-08-20PETER P. PFREUNDSCHUHChief Financial OfficerSell1,416.0033.0746,827.122,751.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119047107/0001209191-19-047107-index.htm
2019-11-20PETER P. PFREUNDSCHUHChief Financial OfficerSell354.0028.4110,057.143,439.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119057753/0001209191-19-057753-index.htm
2019-11-20PETER P. PFREUNDSCHUHChief Financial OfficerBuy1,042.003,793.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119057753/0001209191-19-057753-index.htm
2019-08-20PETER P. PFREUNDSCHUHChief Financial OfficerBuy4,167.004,167.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119047107/0001209191-19-047107-index.htm
2019-02-14Stephen MullennixChief Operating OfficerSell2,804.0037.30104,589.204,230.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119017932/0001209191-19-017932-index.htm
2019-03-06Mark SchoenbergChief Medical OfficerSell1,991.0037.3074,264.304,338.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119017933/0001209191-19-017933-index.htm
2020-01-27PETER P. PFREUNDSCHUHChief Financial OfficerSell667.0029.2819,529.764,438.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120005215/0001209191-20-005215-index.htm
2019-03-21Mark SchoenbergChief Medical OfficerBuy272.0037.0110,066.454,610.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119021092/0001209191-19-021092-index.htm
2020-01-26PETER P. PFREUNDSCHUHChief Financial OfficerBuy1,666.005,105.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120005215/0001209191-20-005215-index.htm
2019-05-14Stephen MullennixChief Operating OfficerSell608.0037.9823,091.845,381.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119030594/0001209191-19-030594-index.htm
2019-06-04Mark SchoenbergChief Medical OfficerBuy1,042.005,652.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119035245/0001209191-19-035245-index.htm
2019-05-14Stephen MullennixChief Operating OfficerBuy1,759.005,989.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119030594/0001209191-19-030594-index.htm
2019-09-04Mark SchoenbergChief Medical OfficerSell343.0033.9211,634.566,007.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119048672/0001209191-19-048672-index.htm
2020-02-20PETER P. PFREUNDSCHUHChief Financial OfficerSell360.0029.6810,684.806,120.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120012017/0001209191-20-012017-index.htm
2019-03-04Mark SchoenbergChief Medical OfficerBuy1,042.006,329.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119017933/0001209191-19-017933-index.htm
2019-09-04Mark SchoenbergChief Medical OfficerBuy1,041.006,350.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119048672/0001209191-19-048672-index.htm
2020-04-27PETER P. PFREUNDSCHUHChief Financial OfficerSell141.0024.353,433.356,396.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120025903/0001209191-20-025903-index.htm
2020-02-20PETER P. PFREUNDSCHUHChief Financial OfficerBuy1,042.006,480.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120012017/0001209191-20-012017-index.htm
2019-08-15Stephen MullennixChief Operating OfficerSell608.0031.6519,243.206,532.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119046282/0001209191-19-046282-index.htm
2020-04-26PETER P. PFREUNDSCHUHChief Financial OfficerBuy417.006,537.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120025903/0001209191-20-025903-index.htm
2019-02-14Stephen MullennixChief Operating OfficerBuy7,034.007,034.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119017932/0001209191-19-017932-index.htm
2020-05-20PETER P. PFREUNDSCHUHChief Financial OfficerSell358.0025.078,975.067,079.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120030900/0001209191-20-030900-index.htm
2019-08-14Stephen MullennixChief Operating OfficerBuy1,759.007,140.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119046282/0001209191-19-046282-index.htm
2020-07-27PETER P. PFREUNDSCHUHChief Financial OfficerSell141.0023.513,314.917,355.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120043874/0001209191-20-043874-index.htm
2020-05-20PETER P. PFREUNDSCHUHChief Financial OfficerBuy1,041.007,437.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120030900/0001209191-20-030900-index.htm
2020-07-26PETER P. PFREUNDSCHUHChief Financial OfficerBuy417.007,496.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120043874/0001209191-20-043874-index.htm
2019-11-14Stephen MullennixChief Operating OfficerSell608.0026.0015,806.367,683.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119056923/0001209191-19-056923-index.htm
2020-09-01PETER P. PFREUNDSCHUHChief Financial OfficerSell509.0022.8211,615.387,888.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120048883/0001209191-20-048883-index.htm
2019-11-19Mark SchoenbergChief Medical OfficerBuy1,960.0028.1755,213.207,967.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119057692/0001209191-19-057692-index.htm
2019-11-14Stephen MullennixChief Operating OfficerBuy1,759.008,291.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119056923/0001209191-19-056923-index.htm
2020-09-01PETER P. PFREUNDSCHUHChief Financial OfficerBuy1,042.008,397.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120048883/0001209191-20-048883-index.htm
2020-01-27Stephen MullennixChief Operating OfficerSell684.0029.2620,013.848,665.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120005211/0001209191-20-005211-index.htm
2019-12-04Mark SchoenbergChief Medical OfficerBuy1,042.009,009.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119059250/0001209191-19-059250-index.htm
2019-11-20Elizabeth A. BarrettChief Executive OfficerBuy7,470.0028.00209,160.009,018.00https://www.sec.gov/Archives/edgar/data/1668243/000120919119057755/0001209191-19-057755-index.htm
2020-01-27Mark SchoenbergChief Medical OfficerSell322.0029.159,386.309,177.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120005200/0001209191-20-005200-index.htm
2020-01-26Stephen MullennixChief Operating OfficerBuy1,666.009,349.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120005211/0001209191-20-005211-index.htm
2020-01-26Mark SchoenbergChief Medical OfficerBuy833.009,499.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120005200/0001209191-20-005200-index.htm
2020-02-14Stephen MullennixChief Operating OfficerSell612.0028.0417,160.489,812.00https://www.sec.gov/Archives/edgar/data/1668243/000120919120009943/0001209191-20-009943-index.htm